Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026.
Claassen is Professor of Neurology at Vanderbilt University Medical Center, where he previously served as Chief of the Division of Behavioral and Cognitive Neurology.
He also serves as Chief Executive Officer of the Huntington's Study Group, where he oversees international research initiatives and organizational strategy to accelerate therapy development.
Speaking about the appointment, Claassen said, "I look forward to guiding the clinical development of ATH434 in MSA and helping bring additional novel therapeutic candidates into the clinic."
ATHE closed trading at $3.4, down 1.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.